Chronic neuropathic pain therapy reshapes around novel sodium channel mechanisms
Suzetrigine (Nav1.8 inhibitor) acute pain approval and follow-on Nav1.8 and Nav1.7 programs in chronic pain are reshaping non-opioid pain management.
Chronic pain pharmacotherapy has been a duloxetine-pregabalin-gabapentin and opioid category. Suzetrigine (Nav1.8 inhibitor) has approval for moderate-to-severe acute pain as the first non-opioid mechanism class with that profile, follow-on Nav1.8 programs in chronic pain conditions (chronic low back pain, diabetic peripheral neuropathy, others) are in late-stage trials, and Nav1.7-targeted programs are reading out. The category is acquiring meaningful non-opioid mechanism-targeted pharmacotherapy.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.